Patent · US Active

Bi-specific fusion proteins

US10988547B2 · kind B2 · utility

4Cited by

23References

7Claims

0Family size

Assignee

Silver Creek Pharmaceuticals, Inc. · US

Inventors

Ulrik Nielsen · Quincy, US
Thomas Wickham · Groton, US
Birgit Schoeberl · Cambridge, US
Brian Harms · Brookline, US
Bryan Linggi · Richland, US
Matthew Onsum · Corona, US
Byron DeLaBarre · Arlington, US
Shaun M. Lippow · Somerville, US

Key dates

Filing date	Jul 29, 2019
Grant date	Apr 27, 2021
Priority date	—
Expiry date	Jul 29, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/80
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.